SCHEMBL5838534

SCHEMBL5838534

Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@@H](N)CC(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCC3 O15438 1/20 0.55
ABCC4 O15439 1/20 0.55
ABCB11 O95342 1/20 0.55
PGR P06401 1/20 0.55
ABCB1 P08183 1/20 0.55
CYP3A4 P08684 1/20 0.55
ADORA3 P0DMS8 1/20 0.55
CHRM1 P11229 1/20 0.55
TBXA2R P21731 1/20 0.55
ADRA1A P35348 1/20 0.55
OPRM1 P35372 1/20 0.55
HTR2B P41595 1/20 0.55
KCNH2 Q12809 1/20 0.55
SCN5A Q14524 1/20 0.55
ABCG2 Q9UNQ0 1/20 0.55
KMT2A Q03164 1/20 0.50
SCN4A P35499 1/20 0.49
APP P05067 1/20 0.43
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7810245 0.95 ADORA3 (0.55) ABCC3ABCC4ABCB11PGRABCB1
SCHEMBL7387546 0.95 ADORA3 (0.55) ABCC3ABCC4ABCB11PGRABCB1
SCHEMBL22305236 0.95 ADORA3 (0.55) ABCC3ABCC4ABCB11PGRABCB1
SCHEMBL7600467 0.95 ADORA3 (0.55) ABCC3ABCC4ABCB11PGRABCB1
SCHEMBL10031780 0.95 ADORA3 (0.55) ABCC3ABCC4ABCB11PGRABCB1
SCHEMBL672415 0.95 ADORA3 (0.55) ABCC3ABCC4ABCB11PGRABCB1
SCHEMBL4956494 0.89 CYP3A4 (0.57) ABCC3ABCC4ABCB11PGRABCB1
SCHEMBL13536317 0.87 ABCC3 (0.58) ABCC3ABCC4ABCB11PGRABCB1
SCHEMBL30261823 0.85 ABCC3 (0.65) ABCC3ABCC4ABCB11PGRABCB1
SCHEMBL8261274 0.85 ABCC3 (0.58) ABCC3ABCC4ABCB11PGRABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132420-B2 Aspartic protease inhibitors THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2006-11-07 US disclosed
EP-1140846-B1 ASPARTIC PROTEASE INHIBITORS US GOV HEALTH & HUMAN SERV (US) 2006-04-05 EP disclosed
US-20050090546-A1 Aspartic protease inhibitors GOVERNMENT OF THE USA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2005-04-28 US disclosed
US-6613764-B1 Compounds such as N,N-dibenzylphenylalanine benzyl ester, used as enzyme inhibitors; prophylaxis of lymphadenopathy associated virus, cancer and malaria THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 2003-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090546-A1 Aspartic protease inhibitors DPP7, SENP7, DNPEP ABCC3 1990/4885ABCC4 2477/4885ABCB11 2323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.